Literature DB >> 27743027

Rationale and evidence to combine radiation therapy and immunotherapy for cancer treatment.

Dan Ishihara1, Laurentiu Pop2, Tsuguhide Takeshima1, Puneeth Iyengar1, Raquibul Hannan3.   

Abstract

Cancer immunotherapy exploits the immune system's ability to differentiate between tumor target cells and host cells. Except for limited success against a few tumor types, most immunotherapies have not achieved the desired clinical efficacy until recently. The field of cancer immunotherapy has flourished with a variety of new agents for clinical use, and remarkable progress has been made in the design of effective immunotherapeutic regimens. Furthermore, the therapeutic outcome of these novel agents is enhanced when combined with conventional cancer treatment modalities including radiotherapy (RT). An increasing number of studies have demonstrated the abscopal effect, an immunologic response occurring in cancer sites distant from irradiated areas. The present work reviews studies on the combination between RT and immunotherapy to induce synergistic and abscopal effects involved in cancer immunomodulation. Further insight into the complex interactions between the immune system and cancer cells in the tumor microenvironment, and their modulation by RT, may reveal the abscopal effect as a clinically relevant and reproducible event leading to improved cancer outcome.

Entities:  

Keywords:  Abscopal effect; Immunotherapy; Radiotherapy; Tumor immunity

Mesh:

Year:  2016        PMID: 27743027     DOI: 10.1007/s00262-016-1914-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  18 in total

Review 1.  In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology.

Authors:  Chenkai Mao; Michael-Joseph Gorbet; Akansha Singh; Ashish Ranjan; Steven Fiering
Journal:  Int J Hyperthermia       Date:  2020-12       Impact factor: 3.914

2.  Stereotactic body radiation therapy and thymosin alpha-1-induced anti-tumor effects in heavily pretreated, metastatic esophageal squamous cell carcinoma patients.

Authors:  Dexi Du; Tao Song; Hui Dai; Zhao Jing; Peng Chen; Shixiu Wu
Journal:  Oncoimmunology       Date:  2018-04-09       Impact factor: 8.110

3.  Antitumor in situ vaccination effect of TNFα and IL-12 plasmid DNA electrotransfer in a murine melanoma model.

Authors:  Urska Kamensek; Maja Cemazar; Ursa Lampreht Tratar; Katja Ursic; Gregor Sersa
Journal:  Cancer Immunol Immunother       Date:  2018-02-21       Impact factor: 6.968

4.  Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.

Authors:  Sharareh Niknam; Hampartsoum B Barsoumian; Jonathan E Schoenhals; Heather L Jackson; Niranjan Yanamandra; Mauricio S Caetano; Ailin Li; Ahmed I Younes; Alexandra Cadena; Taylor R Cushman; Joe Y Chang; Quynh N Nguyen; Daniel R Gomez; Adi Diab; John V Heymach; Patrick Hwu; Maria Angelica Cortez; James W Welsh
Journal:  Clin Cancer Res       Date:  2018-05-21       Impact factor: 12.531

5.  Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy.

Authors:  Osama Mohamad; Alberto Diaz de Leon; Samuel Schroeder; Andrew Leiker; Alana Christie; Elizabeth Zhang-Velten; Lakshya Trivedi; Saad Khan; Neil B Desai; Aaron Laine; Kevin Albuquerque; Puneeth Iyengar; Yull Arriaga; Kevin Courtney; David E Gerber; Hans Hammers; Hak Choy; Robert Timmerman; James Brugarolas; Raquibul Hannan
Journal:  Oncoimmunology       Date:  2018-03-15       Impact factor: 8.110

6.  Renal Cell Carcinoma Pseudoprogression with Clinical Deterioration: To Hospice and Back.

Authors:  Roy Elias; Payal Kapur; Ivan Pedrosa; James Brugarolas
Journal:  Clin Genitourin Cancer       Date:  2018-07-20       Impact factor: 2.872

Review 7.  Advantages and Limitations in the Use of Combination Therapies with Charged Particle Radiation Therapy.

Authors:  Koji Tsuboi
Journal:  Int J Part Ther       Date:  2018-09-21

Review 8.  Recent advances in radiation oncology.

Authors:  Cristina Garibaldi; Barbara Alicja Jereczek-Fossa; Giulia Marvaso; Samantha Dicuonzo; Damaris Patricia Rojas; Federica Cattani; Anna Starzyńska; Delia Ciardo; Alessia Surgo; Maria Cristina Leonardi; Rosalinda Ricotti
Journal:  Ecancermedicalscience       Date:  2017-11-30

Review 9.  Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.

Authors:  Ece Esin
Journal:  Biomed Res Int       Date:  2017-08-07       Impact factor: 3.411

Review 10.  Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?

Authors:  Lizza E L Hendriks; Jordi Remon; Jessica Menis; Benjamin Besse
Journal:  Transl Lung Cancer Res       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.